Given the efficacy of single-agent immunomodulatory agent lenalidomide and HDAC inhibitor romidepsin in PTCL, the combination of immunomodulation and epigenetic manipulation has the potential synergy to target both tumor microenvironment and tumor cells. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.